Questions Patients Commonly Ask About the GLP-1 Drug List
Nearly every question about this drug list traces back to three confusions: brand names against molecules, diabetes labels against weight labels, and approved products against agents still in trials. Untangling those three answers most of what people ask, because the real list is shorter and far more rigid than it appears from the outside.
By Dr. Julie Taylor, MD, MPH
Why does one drug have two names?
Because each version was reviewed for a different purpose. Novo Nordisk submitted semaglutide for type 2 diabetes as Ozempic and later for weight management as Wegovy. Eli Lilly did the same with tirzepatide, filing Mounjaro for diabetes and Zepbound for weight. Liraglutide follows the identical pattern with Victoza and Saxenda.
The chemistry inside is the same. The dose ranges studied, the pen presentation, the price, and above all the wording on the label are not. Insurers read the label wording, which is why the brand split is not a marketing quirk to be ignored.
| Active drug | Brand pair | How it acts | What each brand is approved to treat |
|---|---|---|---|
| Semaglutide | Ozempic and Wegovy | Single GLP-1 receptor agonist | Ozempic for type 2 diabetes with heart and kidney outcome uses; Wegovy for long-term weight reduction, cardiovascular risk reduction, and liver fibrosis in MASH |
| Tirzepatide | Mounjaro and Zepbound | Dual GIP and GLP-1 receptor agonist | Mounjaro for type 2 diabetes; Zepbound for long-term weight reduction and for moderate to severe obstructive sleep apnea with obesity |
| Liraglutide | Victoza and Saxenda | Single GLP-1 receptor agonist, daily | Victoza for type 2 diabetes; Saxenda for long-term weight reduction in adults and eligible patients aged 12 and over |
| Dulaglutide | Trulicity | Single GLP-1 receptor agonist | Type 2 diabetes only, with a cardiovascular risk reduction use in that population |
| Exenatide | Byetta | Single GLP-1 receptor agonist, twice daily | Type 2 diabetes only |
Is Ozempic a weight loss drug?
Not on its label. Ozempic is approved for glycemic control in adults with type 2 diabetes, for reducing major adverse cardiovascular events in that group with established cardiovascular disease, and for slowing kidney function decline in type 2 diabetes with chronic kidney disease. Weight reduction appears in its trial data as an effect, not as an approved use.
The weight indication for semaglutide belongs to Wegovy. The distinction became blurry in public conversation because the same molecule sits in both pens, and because during the shortage years many people were prescribed the diabetes version off label. Coverage decisions, dose ceilings, and supply allocation all still follow the label rather than the molecule.
Is tirzepatide even a GLP-1 drug?
Partly. Tirzepatide activates the GLP-1 receptor and also the receptor for glucose-dependent insulinotropic polypeptide, a second gut hormone. It is usually filed under the GLP-1 heading for convenience, but pharmacologically it is a dual agonist, and the added GIP activity is the reason it is discussed separately in the literature on mechanism.
Whether that second target explains the larger average weight reductions seen in tirzepatide trials remains an open research question. The receptor difference is established. The full explanation for the size of the effect is not.
Why not just ask for the strongest one?
Because strength is not the variable most people run into. The obstacle is nearly always eligibility and price. A product only reaches a patient if a prescriber can justify it against the label, an insurer agrees to fund it or the person pays cash, and the pharmacy has stock.
Cash pricing has become a real part of that arithmetic. Ro, Hims and Hers, and LifeMD publish program prices, and older commercial programs such as WeightWatchers Clinic bundle medication access with coaching. Physician-supervised cash services including formblends.com post a monthly figure for compounded semaglutide and tirzepatide before any appointment is booked. Those routes are not comparable on price alone, since some tiers supply brand medication and others supply compounded preparations, and the two are different products with different regulatory standing.
What about the drugs in the news that nobody can get?
Retatrutide, survodutide, and CagriSema are investigational, while orforglipron has since been approved as an oral product. They have published trial results, sometimes impressive ones, and no approved status. A drug with positive phase results is not on any prescriber’s list until review is complete, and no reliable timeline can be assumed from press coverage.
Anything sold today under one of those names is not the studied agent. That distinction matters more in this class than in most, because demand has outrun supply repeatedly since 2021.
Do compounded versions count as being on the list?
No. Compounded semaglutide and tirzepatide are made by compounding pharmacies and have never been through FDA approval. They are not generics, because none of these molecules has a generic approved in the United States. FDA has published warnings about unapproved GLP-1 products marketed for weight loss, including cases where patients drew the wrong volume from a vial and required treatment.
People still choose them, mostly because the cash cost is lower and access is faster. That choice is more defensible when the person making it knows they are buying something outside the approval system rather than a cheaper edition of the same thing.
What happens when treatment stops?
Weight tends to return. The extension analysis of the semaglutide obesity trial found participants regained roughly two thirds of their lost weight in the year after withdrawal, and a maintenance trial showed continued treatment held reductions while switching to placebo did not. The pattern is consistent across the class and is the strongest argument for treating affordability as a clinical variable rather than a billing detail.
Because the drug keeps working only while it is taken, the cost of staying on it becomes the number that decides most courses. That is where the cash providers compete openly. Henry Meds, LillyDirect, and HealthRX each advertise ongoing pricing for GLP-1 medications, and the figure worth weighing is not the first month but the twelfth, since a plan someone drops on cost recreates the regain the withdrawal data describes.
Frequently asked questions
Can someone switch between these drugs?
Switching happens regularly, usually for tolerance, cost, or supply. Doses are not equivalent across molecules, so a switch restarts escalation from a low dose rather than continuing at the same milligram figure. That restart is why switching often feels like a step backward for several weeks.
Are the older diabetes agents obsolete?
No. Dulaglutide and exenatide remain approved and prescribed for type 2 diabetes, and dulaglutide carries cardiovascular outcome evidence. They simply do not compete on weight reduction, so they rarely appear in conversations driven by that outcome.
Does a longer list mean more choice at the pharmacy counter?
Rarely. Several entries are the same molecule under a second brand, and formulary placement narrows the field again. Most patients end up choosing between two or three real options once the diagnosis, the plan, and local stock are all applied.
Is the sleep apnea approval separate from weight loss?
It is a distinct indication on the Zepbound label, supported by a trial in adults with obesity and moderate to severe obstructive sleep apnea that used breathing events during sleep as its primary measure. Weight reduction occurred alongside it, but the endpoint was respiratory.
Do these drugs have to be injected?
Not universally. Most products in the class are injections, though semaglutide also has tablet formulations with their own labels and dosing rules. Tablets are not interchangeable with injections on a milligram basis and carry separate administration requirements.